These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1720 related articles for article (PubMed ID: 16492545)

  • 21. Selective amylin inhibition of the glucagon response to arginine is extrinsic to the pancreas.
    Silvestre RA; Rodríguez-Gallardo J; Jodka C; Parkes DG; Pittner RA; Young AA; Marco J
    Am J Physiol Endocrinol Metab; 2001 Mar; 280(3):E443-9. PubMed ID: 11171599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue expression and secretion of amylin.
    Young A
    Adv Pharmacol; 2005; 52():19-45. PubMed ID: 16492539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes.
    Nauck MA; Holst JJ; Willms B; Schmiegel W
    Exp Clin Endocrinol Diabetes; 1997; 105(4):187-95. PubMed ID: 9285204
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Islet cell function: alpha and beta cells--partners towards normoglycaemia.
    Göke B
    Int J Clin Pract Suppl; 2008 Mar; (159):2-7. PubMed ID: 18269435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of ketone bodies on glucose production and utilization in the miniature pig.
    Müller MJ; Paschen U; Seitz HJ
    J Clin Invest; 1984 Jul; 74(1):249-61. PubMed ID: 6376544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects on digestive secretions.
    Young A
    Adv Pharmacol; 2005; 52():123-50. PubMed ID: 16492544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Islet amyloid polypeptide: mechanisms of amyloidogenesis in the pancreatic islets and potential roles in diabetes mellitus.
    Johnson KH; O'Brien TD; Betsholtz C; Westermark P
    Lab Invest; 1992 May; 66(5):522-35. PubMed ID: 1573849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabetes mellitus secondary to chronic pancreatitis.
    Larsen S
    Dan Med Bull; 1993 Apr; 40(2):153-62. PubMed ID: 8495594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amylinergic control of food intake.
    Lutz TA
    Physiol Behav; 2006 Nov; 89(4):465-71. PubMed ID: 16697020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of urea synthesis by diet protein and carbohydrate in normal man and in patients with cirrhosis. Relationship to glucagon and insulin.
    Hamberg O
    Dan Med Bull; 1997 Jun; 44(3):225-41. PubMed ID: 9233544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The islet enhancer vildagliptin: mechanisms of improved glucose metabolism.
    Ahrén B; Foley JE
    Int J Clin Pract Suppl; 2008 Mar; (159):8-14. PubMed ID: 18269436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biologic actions and therapeutic potential of the proglucagon-derived peptides.
    Drucker DJ
    Nat Clin Pract Endocrinol Metab; 2005 Nov; 1(1):22-31. PubMed ID: 16929363
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zinc, not insulin, regulates the rat alpha-cell response to hypoglycemia in vivo.
    Zhou H; Zhang T; Harmon JS; Bryan J; Robertson RP
    Diabetes; 2007 Apr; 56(4):1107-12. PubMed ID: 17317764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.
    Knop FK; Holst JJ; Vilsbøll T
    IDrugs; 2008 Jul; 11(7):497-501. PubMed ID: 18600596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 86.